A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 475 participants.

Also called NCT04039503

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 475 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04039503
  • EudraCT 2019-000860-99
Other papers using this trial's data
  • Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial JAMA, 2022-02-08 DOI, PubMed 35133415, PMC8826179 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Czechia, Germany, Japan, Poland, Puerto Rico, Slovakia, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04039503. Randomized; double masking; primary purpose treatment. Start 2019-08-30 (actual); primary completion 2020-12-22 (actual). Results posted on 2022-01-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin
Acronym
SURPASS-5
Intervention (Drug)
Tirzepatide
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct04039503
Content hash
067ff883f80850e483972a27e10282bd53bb7bb24abe2a2e54f6dc0379b31425